BK2011 Diagnostics & Research
- 3986.285
- +27.211+0.69%
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 6.43% on an annualized basis producing an average annual return of 16.92%. Currently, Thermo Fisher Scientific
Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The table below summarizes their recent ratings, s
HC Wainwright & Co. Reiterates Neutral on CareDx
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.
CareDx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 — HC Wainwright & Co. Reiterates → Neutral 05/17/2024 67.81% Craig-Hallum $15 → $22 Maintains
Agilent Technologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 -4.92% Barclays $135 → $125 Maintains Underweight 05/30/2024 2.69% Citigroup $145 → $135 Mainta
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
(NTRA) - Analyzing Natera's Short Interest
Natera's (NYSE:NTRA) short percent of float has fallen 5.87% since its last report. The company recently reported that it has 5.81 million shares sold short, which is 4.97% of all regular shares that
Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Icon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 13.65% Baird $363 → $367 Maintains Outperform 04/26/2024 8.08% TD Cowen $343 → $349 Maintains B
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. This move comes as Robinhood launches
Qualigen Therapeutics Receives Nasdaq Notice of Delisting Determination
Qualigen Therapeutics Received Nasdaq Notice Of A Delisting Determination
Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN), announced today that on May 23, 2024, it received written notice (the "Delist Notice") from The Nasdaq Stock Market ("Nasdaq") i
Piper Sandler's Actionable Trading Ideas: 3 Positive, 3 Negative
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish.
TD Cowen Maintains Buy on Agilent Technologies, Lowers Price Target to $153
TD Cowen analyst Dan Brennan maintains Agilent Technologies (NYSE:A) with a Buy and lowers the price target from $163 to $153.
Labcorp Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 26.23% JP Morgan $261 → $243 Maintains Overweight 04/26/2024 32.47% Truist Securities $270 → $2
Tech, Blue Chip Stocks Drop; Small Caps, Real Estate Rebound As Yields Ease; Solar Industry Shines: What's Driving Markets Thursday?
Wall Street experienced another decline on Thursday, with major large-cap indices affected by a downturn in the tech and communication services sectors. Investors shifted their focus to market areas t
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 11.68% JP Morgan $152 → $155 Maintains Neutral 04/25/2024 3.75% Barclays $138 → $144 Maintains
Cracking The Code: Understanding Analyst Reviews For Agilent Technologies
Analysts' ratings for Agilent Technologies (NYSE:A) over the last quarter vary from bullish to bearish, as provided by 9 analysts.Summarizing their recent assessments, the table below illustrates the